Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for Irritability in Autism (ANCHOR)
NCT04174365Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in Autism Spectrum Disorder (ASD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2019; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04174365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174365.